Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Plain-language summary

This study examines Sofosbuvir/Velpatasvir (SOF/VEL) treatment in adults with chronic hepatitis C virus (HCV) infection who are on dialysis for end stage renal disease. It enrolled adults aged 18 and over on dialysis, including those co-infected with HIV who were stable on treatment. The study was carried out in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Gilead Sciences

Intervention

SOF/VEL

Start date

3/22/2017

Estimated completion

11/7/2018

Countries

Australia, Canada, Israel, New Zealand, Spain, United Kingdom

Related genes

Locations

• Adelaide, Australia
• Edmonton, Canada
• Vancouver, Canada
• Brampton, Canada
• Hamilton, Canada
• Ottawa, Canada
• Montreal, Canada
• Jerusalem, Israel
• Ramat Gan, Israel
• Tel Aviv, Israel
• Grafton, New Zealand
• Alcorcón, Spain
• Barcelona, Spain
• Majadahonda, Spain
• Seville, Spain
• Glasgow, United Kingdom
• London, United Kingdom
• London, United Kingdom
• London, United Kingdom
• London, United Kingdom
• Nottingham, United Kingdom
• Plymouth, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Key Inclusion Criteria:

* Chronic HCV infected, male and non-pregnant/non-lactating females aged 18 years or older who are on dialysis for ESRD, including adults with HIV co-infection if they are suppressed on a stable, protocol-approved antiretroviral (ARV) regimen for ≥8 weeks prior to screening.

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.